Fecal Microbiota, Live-jslm (RBL; REBYOTA®) for Prevention of Recurrent Clostridioides difficile Infection

Abstract

Live biotherapeutic products (LBPs) such as fecal microbiota, live-jslm (RBL) are becoming more frequently administered in gastroentintestinal (GI) care settings. As a result, GI nurses must be knowledgeable about and skilled in their administration of LBPs. RBL is a single-dose, rectally-administered, microbiota-based LBP suspension indicated for prevention of recurrent Clostridioides difficile infection (rCDI). RBL contains a diverse set of micro-organisms, including Bacteroides spp., and is believed to restore a healthy gut microbiota to mitigate dysbiosis associated with rCDI. Patients do not require fasting, bowel preparation, or anesthesia prior to RBL administration. Administration takes approximately 5 minutes and can be given by any health care professional (e.g., nurses) in any care setting. Nurses also play an important role in educating patients and caregivers about these products and the disease. Collectively, improved familiarity with LBPs and their proper use among nurses can contribute to successful prevention of rCDI in their patients.